L. Vetrone

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge

S. Fanti, C. Gaudiano, A. Cappelli, 2023, Frontiers in Oncology.

Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma

V. Tombolini, D. Musio, N. Bulzonetti, 2019, Medical Oncology.

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with 68Ga-PSMA PET/CT Features in Primary Staging

S. Fanti, R. Schiavina*, E. Brunocilla, 2023, Cancers.

Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?

S. Fanti, P. Castellucci, E. Fortunati, 2023, Seminars in nuclear medicine.

A novel tool for predicting the dose distribution of non-sealed 188 Re (Rhenium) resin in non-melanoma skin cancers (NMSC) patients.

S. Fanti, L. Strigari, A. Morganti, 2023, Medical Physics (Lancaster).

Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection

E. Brunocilla, P. Castellucci, A. Farolfi, 2024, Frontiers in Oncology.